TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
Bignotti E, Simeon V, Ardighieri L, Kuhn E, Marchini S, Califano D, Cecere SC, Bugatti M, Spina A, Scognamiglio G, Paracchini L, Russo D, Arenare L, Tognon G, Lorusso D, Beltrame L, D'Incalci M, Sartori E, De Censi A, Odicino F, Perrone F, Chiodini P, Pignata S.
Bignotti E, et al. Among authors: sartori e.
Int J Cancer. 2025 Mar 1;156(5):1085-1096. doi: 10.1002/ijc.35203. Epub 2024 Oct 16.
Int J Cancer. 2025.
PMID: 39415516
Free PMC article.